June 2, 2022 --Genentech, a member of the Roche Group, recently announced that the U.S. Food and Drug Administration (FDA) has approved a label extension for Evrysdi? (risdiplam) to include babies under two months old wi……
May 25, 2022-Sanofi and its partner Regeneron jointly announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent? (dupilumab) 300 mg weekly to treat patients with eosinophilic esophagitis (EoE)……
May 23, 2022- The U.S. Food and Drug Administration (FDA) approved Mounjaro? (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP (glucose-dependent insulinotropic……
Apr. 20, 2022-Takeda today announced that the Phase 3 SHP643-302 study evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO? (lanadelumab) in patients 2 to ……
Marketing Authorisation Holder:EU guidance states that the ultimate responsibility for the performance of a medicinal product over its lifetime in relation to its safety, quality and efficacy, lies with the Marketing Aut……
Mar. 24th, 2022-Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders announced that the U.S. Food and Drug Administrati……
Copyright Nanjing Dorra Pharmaceutical Technology Co.,Ltd. @ 2018 China All Rights Reserved 蘇ICP備12056923號-1
Tel: 025-82232955 025-82232966
Fax:025-82232933 025-82232944
E-mail: info@dorrapharma.com
